Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis

Study Title

Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)

Teva Identifier

ALS-GA-201

ClinicalTrials.gov Identifier

NCT00326625

Study Status

Completed

Trial Condition(s)

Amyotrophic Lateral Sclerosis

Interventions

Drug: 40 mg glatiramer acetate | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations
neurology icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 70 Years

Trial Duration

July 31, 2006 - July 31, 2008

Phase

Phase 2

Study Type

Interventional